Patients with ovarian cancer who carry BRCA1/2 mutations are very sensitive to platinum‐based chemotherapy with good prognosis (Byrski et al., 2012), and can benefit from treatment with poly ADP‐ribosome polymerase inhibitors (Isakoff, 2010; Rouleau, Patel, Hendzel, Kaufmann, & Poirier, 2010; Ström et al., 2011). This evidence concerns the gene BRCA1 and ovarian cancer.